Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05950906 · ClinicalTrials.gov registry record · Phase 1
Study to Assess PDM608 in Healthy Adult Subjects
A Phase 1 study, sponsored by Calibr, a division of Scripps Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT05950906 is a Phase 1 study that has completed, run by Calibr, a division of Scripps Research. The registered enrollment target is 64 participants.
The verdict
NCT05950906, a Phase 1 study, has completed, sponsored by Calibr, a division of Scripps Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG PDM608
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05950906
The ClinicalTrials.gov registry entry for NCT05950906 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calibr, a division of Scripps Research, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05950906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05950906 about?
NCT05950906 is a clinical study titled "Study to Assess PDM608 in Healthy Adult Subjects". The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.
What is the current status of trial NCT05950906?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2023-06-27. Estimated completion is 2024-04-19.
What interventions are being tested in trial NCT05950906?
The interventions under investigation include: Placebo (DRUG), PDM608 (DRUG).
Who is sponsoring clinical trial NCT05950906?
This trial is sponsored by Calibr, a division of Scripps Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.